Some keep claiming that the OA market is 10
times the RA market. Are you suggesting that
the sales value potential for iPPS for OA is
10 times the size of Humira RA. If so, that is
rather misleading. A years supply of Humira in
the US costs around $84,000. A course of iPPS, which
which probably would not be repeated for 12 months,
we are suggesting will cost (ball park) between
$3000 and $6000, depending on DMOAD trial
results. Still a mightily handsome yearly revenue,
but do you see the discrepancy in the revenue
expectations for OA.
The Humira comparative, and how about a bonus?, page-9
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $323.1K | 1.612M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 324 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 52928 | 5 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |